Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis

Tropical Medicine and International Health

Volumn 7, Issue 9, 2002, Pages 775-779

  Mpia, Bokelo ^a   Pépin, Jacques ^b  

^a Hôpital de Nioki   (Democratic Republic Congo)

^b Centre for International Health   (Canada)

Author keywords

African trypanosomiasis; Democratic Republic of Congo; Eflornithine; Melarsoprol; Trypanosoma brucei gambiense

Indexed keywords

CHLOROQUINE; EFLORNITHINE; MEBENDAZOLE; MELARSOPROL;

DISEASE CONTROL; DRUG PRESCRIBING; DRUG RESISTANCE; PERFORMANCE ASSESSMENT; TOXICITY; TRYPANOSOMIASIS;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; MONOTHERAPY; RECURRENT DISEASE; SURVIVAL; TREATMENT OUTCOME; TRYPANOSOMA; TRYPANOSOMIASIS;

ADOLESCENT; ADULT; CONGO; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EFLORNITHINE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MELARSOPROL; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS;

DEMOCRATIC REPUBLIC CONGO;

PROTOZOA; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA BRUCEI GAMBIENSE;

EID: 0036378279     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2002.00933.x     Document Type: Article

References (23)

1. Bacchi CJ, Nathan HC, Clarkson AB et al. (1990) Effect of ornithine decarboxylase inhibitors DL-α-difluoromethylornithine and α-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. American Journal of Tropical Medicine and Hygiene 33, 46-52.
2. Bacchi CJ, Nathan HC, Livingston T et al. (1990) Differential susceptibility to DL-α-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrobial Agents and Chemotherapy 34, 1183-1188.
3. Bacchi CJ, Nathan HC, Yarlett N et al. (1994) Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-α-difluoromethylornithine and standard trypanocides. Antimicrobial Agents and Chemotherapy 38, 563-569.
4. Fairlamb AH (1990) Novel approaches to the chemotherapy of trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 84, 613-617.
5. Fairlamb AH, Blackburn P, Ulrich P, Chait BT & Cerami A (1985) Trypanothione: a novel bis(glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science 227, 1485-1487.
6. Iten M, Mett H, Evans A, Enyaru JCK, Brun R, Kaminsky R (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to DL-α- dilfuoromethylornithine. Antimicrobial Agents and Chemotherapy 41, 1922-1925.
7. Jennings FW (1988a) Chemotherapy of trypanosomiasis: the potentiation of melarsoprol by concurrent difluoromethylorni-thine (DFMO) treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 82, 572-573.
8. Jennings FW (1988b) The potentiation of arsenicals with difluo-romethylornithine (DFMO): experimental studies in murine trypanosomiasis. Bulletin de la Société de Pathologie Exotique et de Ses Filiales 81, 595-607.
9. Jennings FW (1990) Future prospects for the chemotherapy of human trypanosomiasis. 2. Combination therapy and African trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 84, 618-621.
10. Jennings FW (1993) Combination therapy of CNS trypanosomiasis. Acta Tropica 54, 205-213.
11. Khonde N, Pépin J & Mpia B (1997) A seven days course of eflornithine for relapsing T.b. gambiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene 91, 212-213.
12. Legros D, Evans S, Maiso F, Enyaru JCK & Mbulamberi D (1999) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 93, 439-442.
13. Milord F, Loko L, Éthier L, Mpia B & Pépin J (1993) Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 473-477.
14. Milord F, Pépin J, Loko L, Éthier L & Mpia B (1992) Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 340, 652-655.
15. Moore M & Richer M (2001) Re-emergence of epidemic sleeping sickness in southern Sudan. Tropical Medicine and International Health 6, 342-347.
16. Pépin J, Khonde N, Maiso F et al. (2000) Short-course eflornithine in Gambian sleeping sickness: a multicentre randomised controlled trial. Bulletin of the World Health Organization 78, 1284-1295.
17. Pépin J & Méda H (2001) The epidemiology and control of African trypanosomiasis. Advances in Parasitology 49, 71-132.
18. Pépin J & Milord F (1994) The treatment of human African trypanosomiasis. Advances in Parasitology 33, 1-47.
19. Pépin J, Milord F, Khonde A, Niyonsenga T, Loko L & Mpia B (1994) Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Transactions of the Royal Society of Tropical Medicine and Hygiene 88, 447-452.
20. Simarro PP & Asumu PN (1996) Gambian trypanosomiasis and synergism between melarsoprol and eflornithine: first case report. Transactions of the Royal Society of Tropical Medicine and Hygiene 90, 315.
21. Stanghellini A & Josenando T (2001) The situation of sleeping sickness in Angola: a calamity. Tropical Medicine and International Health 6, 330-334.
22. Wang CC (1995) Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annual Review of Pharmacology and Toxicology 35, 93-127.
23. WHO (2001) Companies offer more help for the control of sleeping sickness. TDR News 65, 10.